- Bioventix
- 31 March 2025 13:56:31
Source: Sharecast
The AIM-traded developer of high-affinity monoclonal antibodies for clinical diagnostics generated revenue of £6.73m, up 1% from £6.68m a year earlier.
Profit before tax fell 4% to £5.05m, down from £5.24m, which the company attributed to increased investment in research activities.
Cash balances at the end of the period stood at £5.1m, compared to £5.5m in the prior year.
The board declared an interim dividend of 70p per share, a 3% increase on the prior year’s 68p, reflecting continued confidence in the company’s underlying cash generation and long-term prospects.
“Our core business has performed in line with expectations although troponin revenues did not achieve the growth we hoped for,” said chief executive officer Peter Harrison and chairman Ian Nicholson in a joint statement.
“Increased sales of Tau antibodies for Alzheimer's disease have been a highlight and we continue to remain excited about the future for these antibodies as the scientific output of our collaboration with University of Gothenburg increasingly translates into commercial success.
“We also remain excited about the antibodies we have developed with potential applications outside of our core business and anticipate a return to growth in 2026 and beyond as troponin and Tau revenues become more significant.”
At 1331 GMT, shares in Bioventix were down 10.91% at 2,450p.
Reporting by Josh White for Sharecast.com.